COVID-19 関連細胞

1)新型コロナウイルス感染症に対する理研BRCの取り組み

理研バイオリソース研究センター(理研BRC)は、遺伝子/細胞/マウス個体の三つの生命階層のリソースを1機関で取り揃えた、世界的にもユニークなリソース機関です。この特徴を活かして、新型コロナウイルス感染症の統合的な研究の促進のため、感染症の4つのステージ(①ウイルス感染・増殖、②発症・生体防御、③重症化、④治療・予防)の研究開発の鍵となるバイオリソースを収集・整備し、情報発信していきます。

COVID-19 関連マウスリソース(実験動物開発室)

SARS-CoV-2 relevant human genes(遺伝子材料開発室)


2)COVID-19 関連寄託細胞株 提供を開始しました。

ReferenceBRC Resource特性
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection RCB5391 R52_Spike 抗SARS-CoV-2 Spike抗体(Clone R52)を産生するハイブリドーマ。
RCB5392 S1D7_Spike 抗SARS-CoV-2 Spike抗体(Clone S1D7)を産生するハイブリドーマ。
RCB5393 S3D8_Spike 抗SARS-CoV-2 Spike抗体(Clone S3D8)を産生するハイブリドーマ。

3)BRCから提供した細胞を利用した COVID-19 関連文献

BRC ResourceJournalReference
1RCB2202 293T Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry
2RCB0007 HeLa Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor
3RCB0995 MDCK Clin Infect Dis. 2020 Oct 3;ciaa1517Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19
4RCB0535 RAW 264 Viruses. 2020 Jun 28;12(7):699Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2
5RCB0988 CACO-2
CSII-CMV-MCS-IRES2-Bsd
PLoS Pathog. 2021 Jan 21;17(1):e1009233.SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
6RCB0485 LA-N-5 Sci Rep. 2021 Feb 9;11(1):3379Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
7RCB2202 293T Cell. 2021 Jun 24;184(13):3452-3466.e18An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
8RCB1902 HSC-4 J Anat. 2021 Jun;238(6):1341-1354Expression of SARS‐CoV‐2 entry factors in human oral tissue
9RCB0209 SP2/0-Ag14 J Biol Chem. Jan-Jun 2021;296:100346 Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
10RCB0988 CACO-2
RCB2202 293T
Sci Rep. 2021 Mar 8;11(1):5376 MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
11RCB0988 CACO-2 J Virol. 2022 Mar 23;96(6):e0000222
(bioRxiv. June 30, 2021)
Host cellular RNA helicases regulate SARS-CoV-2 infection
12RCB0211 MRC-5Cell Rep Med. 2021 Jun 15;2(6):100311 Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
13RCB2202 293TbioRxiv. August 23, 2021The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
14RCB0098 A549 Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells
15HPS0002 253G1 J Toxicol Sci. 2021; 46(9):425-435Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing
16RCB0098 A549
RCB0988 CACO-2
RCB1942 HuH-7
iScience. 2021 Oct 22;24(10):1031205-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2
17RCB0771 XTC-YF Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):477-484Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile
18RCB1168 SKW-3 Commun Biol. 2021 Dec 2;4(1):1365Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
19RCB0001 Vero iScience. 2021 Nov 17;103379Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2
20RCB0098 A549
RCB0988 CACO-2
HuH-7
Nat Commun. 2021 Nov 15;12(1):6602SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis
21RCB4557 HUDEP-2 Nat Genet. 2021 Nov;53(11):1606-1615Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
22RCB0995 MDCK J Infect Chemother. 2022 Feb;28(2):252-256.Stability of SARS-CoV-2 and influenza virus varies across different paper types
23RCB0988 CAC0-2 Experimental and Therapeutic Medicine 2022-2-10 Indigo plant leaf extract inhibits the binding of SARS‑CoV‑2 spike protein to angiotensin‑converting enzyme 2
24NIH3T3Cancer Sci. 2022 Aug;113(8):2536-2547 A single immunization with cellular vaccine confers dual protection against SARS-CoV-2 and cancer
25RCB2202 293T J Med Chem. 2022 Oct 27;65(20):13852-13865 Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease
26RCB2202 293T
RCB0001 Vero
Pharm Res. 2022 Sep 26;1-9 Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
27RCB1637 293 Commun Biol. 2022 Nov 5;5(1):1188 ACE2 N-glycosylation modulates interactions with SARS-CoV-2 spike protein in a site-specific manner
28NEWRCB2630 B16F10Cell. 2022 Jun 9;185(12):2103-2115.e19 Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
29NEWRCB0098 A549
RCB2202 293T
J Biol Chem. 2022 Nov;298(11):102500 Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis
30NEWRCB0995 MDCK
RCB2202 293T
J Nat Prod. 2022 Nov 25;85(11):2583-2591 Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant Streptomyces sp. JA74, Exhibiting Antiviral Activity against Influenza and SARS-CoV-2 Viruses
31NEWRC2202 293TSci Transl Med. 2023 Jan 18;15(679):eabq4064S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
32NEWRC2202 293T
RCB0001 Vero
iScience. 2023 Jan 20;26(1):105742Stimulation of interferon-β responses by aberrant SARS-CoV-2 small viral RNAs acting as retinoic acid-inducible gene-I agonists

4)COVID-19 研究のための細胞株

BRC Cell LineCell LineReference
1Vero E6, RCB0001 Vero
RCB0988 CACO-2
Calu-3
RCB2202 293T
RCB1366 HuH-7
Vero E6
Caco-2
Calu-3
HEK293T
Huh7
In Vitro and Animal Models for SARS-CoV-2 research
2Vero E6
RCB0001 Vero
RCB1366 HuH-7
RCB2202 293T
RCB0098 A549, RCB3677 A549
EFKB3
Vero E6
Vero
HUH 7.0
293T
A549
EFKB3
Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
3RCB0001 Vero
RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1366 HuH-7
Vero
HeLa
HEK293T/F
Huh7
A Thermostable mRNA Vaccine against COVID-19
4RCB1637 293
RCB2202 293T
RCB0098 A549, RCB3677 A549
RCB0218 MRC-5, known PDL
Vero E6, RCB0001 Vero
Vero 81
RCB0007 HeLa, RCB3680 HeLa
RCB1366 HuH-7
293
293T
A549
MRC5
Vero E6
Vero 81
HeLa
Huh7
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
5RCB1648 Hep G2
RCB1366 HuH-7
RCB2202 293T
RCB0001 Vero
CHO
RCB0995 MDCK
HepG2
Huh-7
293T
Vero
CHO
MDCK
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
6Vero E6, RCB0001 Vero
RCB1366 HuH-7
Vero E6
Huh-7
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
7Vero E6, RCB0001 Vero
RCB1366 HuH-7
Vero E6
Huh-7
Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
8Vero E6, RCB0001 Vero
RCB1366 HuH-7
Vero E6
Huh-7
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
9Vero E6, RCB0001 Vero
RCB1366 HuH-7
Vero E6
Huh-7
A pneumonia outbreak associated with a new coronavirus of probable bat origin
10RCB1637 293
RCB1366 HuH-7
RCB1423 BHK-21
Vero E6, RCB0001 Vero
HEK293
Huh-7
BHK21
Vero-E6
Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε
11RCB0007 HeLa, RCB3680 HeLa
RCB2202 293T
RCB1423 BHK-21
RCB0988 CACO-2
HeLa
293T
BHK-21
Caco-2
COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
12RCB0988 CACO-2Caco-2Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
13RCB0988 CACO-2Caco-2A metabolic handbook for the COVID-19 pandemic
14RCB2202 293T
RCB0098 A549, RCB3677 A549
BHK
RCB0988 CACO-2
RCB1366 HuH-7
PK-15
293T
A549
BHK
Caco-2
Huh-7.5
PK-15
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
15RCB2202 293T
RCB0098 A549, RCB3677 A549
HEK293T
A549
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
16RCB2202 293T
RCB0007 HeLa, RCB3680 HeLa
Calu-3
RCB0218 MRC-5, known PDL
HEK293T
HeLa
Calu-3
MRC-5
Cell entry mechanisms of SARS-CoV-2
17RCB2202 293T
HEK293F
RCB0007 HeLa, RCB3680 HeLa
RCB0218 MRC-5, known PDL
HEK293T
HEK293F
HeLa
MRC5
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
18RCB1366 HuH-7
Huh-7.5
Huh-7
Huh-7.5
Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
19RCB0994 MA104
RCB1637 293
MA104
HEK293
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
20RCB0218 MRC-5, known PDL MRC-5 Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
21Fcwf-4
A72
RCB0995 MDCK
DH82
Fcwf-4
A72
MDCK
DH82
Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663
22GES-1
RCB1189 THP-1,RCB3686 THP-1
GES-1
THP-1
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels


コメントは受け付けていません。